BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting
November 11, 2016 07:00 ET
|
BeiGene, LTD.
WALTHAM, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for...
BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9
October 04, 2016 16:15 ET
|
BeiGene, LTD.
WALTHAM, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncological drugs for the...